Gene Therapies Push Investors to Examine New Areas of the Human Body

September 15, 2014

(The Wall Street Journal) – Advances in gene therapy are leading venture investors to fund treatments for conditions affecting a wider range of body systems. Venture firms have sunk more dollars into gene therapies since 2010, $715.8 million, than they did all of last decade, $653.6 million, according to VentureSource, which is owned by Dow Jones & Co., publisher of The Wall Street Journal. Investors see the most initial opportunity in neurological, vision and blood disorders. Gene therapies for the brain have raised $503.5 million since 1999, while blood-related gene therapies have raised $224.8 million, and gene therapies for the eyes took in $211.6 million.